N-(cyclohexylmethyl)-N-(pyridin-3-ylmethyl)amine | 137526-39-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(cyclohexylmethyl)-N-(pyridin-3-ylmethyl)amine
• 英文别名: N-(cyclohexylmethyl)-N-(3-pyridylmethyl)amine；cyclohexylmethyl-pyridin-3-ylmethylamine；1-cyclohexyl-N-(pyridin-3-ylmethyl)methanamine
• CAS: 137526-39-7
• 化学式: C₁₃H₂₀N₂
• mdl: MFCD04141878
• 分子量: 204.315
• InChiKey: MQWKOLAHCPSYRR-UHFFFAOYSA-N

物化性质

• 沸点：
  322.8±17.0 °C(Predicted)
• 密度：
  0.988±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.615
• 拓扑面积：
  24.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(cyclohexylmethyl)-N-(pyridin-3-ylmethyl)amine 、 2-(6-fluoro-1H-indol-3-yl)-2-oxoacetyl chloride 在 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 以39%的产率得到N-cycIohexylmethyl-2-(6-fluoro-1H-indol-3-yl)-2-oxo-N-pyridin-3-ylmethylacetamide
  参考文献：
  名称：

  [EN] INDOLE- 3 -GLYOXYLAMIDE DERIVATIVES FOR USE AS CALCIUM ION CHANNEL MODULATORS
  [FR] DÉRIVÉS D'INDOLE-3-GLYOXYLAMIDE DESTINÉS À ÊTRE UTILISÉS COMME MODULATEURS DES CANAUX CALCIQUES

  摘要：

  化合物的化学式（I）可用于治疗一系列疾病，包括疼痛。

  公开号：

  WO2009133387A1
• 作为产物：
  描述：

  3-氨甲基吡啶 、 环己烷基甲醛 在 三乙胺 、 三乙酰氧基硼氢化钠 、 碳酸氢钠 作用下， 以 甲醇 、 乙酸乙酯 为溶剂， 反应 50.0h， 以48%的产率得到N-(cyclohexylmethyl)-N-(pyridin-3-ylmethyl)amine
  参考文献：
  名称：

  [EN] INDOLE- 3 -GLYOXYLAMIDE DERIVATIVES FOR USE AS CALCIUM ION CHANNEL MODULATORS
  [FR] DÉRIVÉS D'INDOLE-3-GLYOXYLAMIDE DESTINÉS À ÊTRE UTILISÉS COMME MODULATEURS DES CANAUX CALCIQUES

  摘要：

  化合物的化学式（I）可用于治疗一系列疾病，包括疼痛。

  公开号：

  WO2009133387A1

文献信息

• [EN] CALCIUM ION CHANNEL MODULATORS & USES THEREOF<br/>[FR] MODULATEURS DES CANAUX IONIQUES CALCIQUES ET LEURS UTILISATIONS
  申请人：LECTUS THERAPEUTICS LTD

  公开号：WO2010035032A1

  公开（公告）日：2010-04-01

  Compounds of formula (I), wherein R1 is hydrogen, hydroxyl or aralkyl; R2 is an optionally substituted alkyl, aryl or heteroaryl (said substituents are selected from hydroxyl, alkoxyl, haloalkoxyl, aryl, heteroaryl, cycloalkyl, amino, monoalkylamino, dialkylamino, alkylsulphonyl, alkylsulphinyl, alkylsulphonylamino, acylamino, saturated or partially unsaturated heterocyclic groups and groups of formula COY); W is selected from oxygen, sulphur, groups of formula NR7, wherein R7 is hydrogen, alkyl, aryl or heteroaryl and groups of formula CR8R9, wherein R8 and R9 are hydrogen, alkyl, aryl or heteroaryl; and X is selected from nitrogen and groups of formula CR10, wherein R10 is hydrogen, alkyl, aryl, heteroaryl, halogen or haloalkyl, inhibit the interaction between Cavx channels and Cavβ proteins and are of use in the treatment and prevention of a number of diseases and conditions including pain and lower urinary tract disorders.

  式(I)中的化合物，其中R1是氢、羟基或芳基烷基；R2是可选择取代的烷基、芳基或杂环芳基（所述取代基选自羟基、烷氧基、卤代烷氧基、芳基、杂环芳基、环烷基、氨基、单烷基氨基、双烷基氨基、烷基磺酰基、烷基亚砜基、烷基磺酰氨基、酰氨基、饱和或部分不饱和的杂环族和式COY）；W选自氧、硫、式NR7的基团，其中R7是氢、烷基、芳基或杂环芳基，以及式CR8R9的基团，其中R8和R9是氢、烷基、芳基或杂环芳基；X选自氮和式CR10的基团，其中R10是氢、烷基、芳基、杂环芳基、卤素或卤代烷基，能够抑制Cavx通道与Cavβ蛋白之间的相互作用，并可用于治疗和预防包括疼痛和下尿路障碍在内的多种疾病和症状。
• Amide derivatives as therapeutic agents
  申请人：——

  公开号：US20030171411A1

  公开（公告）日：2003-09-11

  This invention relates to compounds of the general formula 1 which are activators of glucokinase (GK), and which may be useful for the management, treatment, control, or adjunct treatment of diseases or conditions, where increasing glucokinase activity is beneficial, for example diseases such as IGT, Syndrome X, type 2 diabetes, type 1 diabetes, dyslipidemia, hyperlipidemia, hypertension, and obesity.

  本发明涉及一般式1的化合物，其为葡萄糖激酶（GK）的激活剂，可用于管理、治疗、控制或辅助治疗增加葡萄糖激酶活性有益的疾病或病况，例如IGT、综合征X、2型糖尿病、1型糖尿病、脂质代谢异常、高脂血症、高血压和肥胖症。
• Carbostyril derivative
  申请人：Otsuka Pharmaceutical Co.

  公开号：US05401740A1

  公开（公告）日：1995-03-28

  The novel carbostyril derivative represented by the general formula (1) ##STR1## [in the formula, A, R.sup.1, R.sup.2 and the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton have the same definitions as above] has an excellent platelet aggregation inhibitory activity, a phosphodiesterase inhibitory activity, a venticular contraction activity (a positive contraction activity), an anti-ulcer activity, an anti-inflammatory activity, a cerebral blood flow increasing activity, a thrombus dissociation activity, a thromboxane A.sub.2 antagonism activity, etc. The carbostyril derivative of the present invention is characterized in that it exhibits the above activities for a long time, is low in toxicity (particularly low in toxicity to hearts of cardiovascular hyperplasia, myocardipathy, etc.), and is low in circulation activities such as heart rate increasing activity, blood pressure decreasing activity and the like. Also, the carbostyril derivative of the present invention has advantages in that it is easily absorbed by the intestinal tract and easily migrates into blood. Therefore, the carbostyril derivative of the present invention can be used most suitably as a preventive and remedy for thrombi such as apoplexia, cerebral infarction, myocardial infarction and the like, a cerebral circulation improving agent, an anti-inflammatory agent, an anti-asthmatic agent, a cardiotonic agent and a phosphodiesterase inhibitory agent.

  通式（1）所表示的新型碳基苯并咪唑衍生物 ##STR1## [在公式中，A，R.sup.1，R.sup.2和碳基苯并咪唑骨架中3-和4-位之间的碳-碳键具有与上述相同的定义] 具有出色的血小板聚集抑制活性，磷酸二酯酶抑制活性，室性收缩活性（阳性收缩活性），抗溃疡活性，抗炎活性，增加脑血流活性，溶解血栓活性，血栓素A.sub.2拮抗活性等。本发明的碳基苯并咪唑衍生物的特点在于它表现出上述活性长时间持续，毒性低（特别是对心血管增生，心肌病等心脏毒性低），循环活性如心率增加活性，降低血压活性等也低。此外，本发明的碳基苯并咪唑衍生物具有易被肠道吸收且易进入血液的优点。因此，本发明的碳基苯并咪唑衍生物最适用于预防和治疗像中风，脑梗塞，心肌梗塞等血栓，改善脑循环的药物，抗炎药，抗哮喘药，强心剂和磷酸二酯酶抑制剂。
• CARBOSTYRIL DERIVATIVES
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP0450066A1

  公开（公告）日：1991-10-09

  This invention relates to carbostyril derivatives represented by general formula (1), a process for their preparation, and an agent for inhibiting agglutination of platelets containing them as an active ingredient, wherein A represents a lower alkylene group, R1 represents a substituted or unsubstituted cycloalkyl-lower alkyl group, a cycloalkyl group, a tetrahydropyranyl* lower alkyl group, a lower alkylenedioxy-substituted lower alkyl group, a substituted phenyl-lower alkyl group or a lower alkyl-substituted piperidinyl-lower alkyl group, R2 represents a substituted or unsubstituted 5- or 6-membered, saturated or unsaturated heterocyclic-lower alkyl group, a tetrahydropyranylthio-lower alkyl group, a pyridylthio-lower alkyl group, a lower alkylene-dioxy-substituted lower alkyl group or a substituted or unsubstituted lower alkyl group, and the carbon-to-carbon bond between the 3- position and the 4-position of the carbostyril skeleton represents either a single or a double bond.

  本发明涉及通式(1)代表的碳化二氢吡啶衍生物、其制备工艺以及含有其作为活性成分的抑制血小板凝集的制剂，其中A代表低级亚烷基，R1代表取代或未取代的环烷基-低级烷基、环烷基、四氢吡喃基*低级烷基、低级亚烷基-二氧基取代的低级烷基、取代的苯基-低级烷基或低级烷基-取代的哌啶基-低级烷基、R2 代表取代或未取代的 5 或 6 元、饱和或不饱和杂环低级烷基、四氢吡喃硫基低级烷基、吡啶硫基低级烷基、亚烷基二氧基取代的低级烷基或取代或未取代的低级烷基，碳四吡啶骨架的 3 位和 4 位之间的碳-碳键代表单键或双键。
• Amide derivatives useful as glucokinase activators
  申请人：Novo Nordisk A/S

  公开号：EP2305648A1

  公开（公告）日：2011-04-06

  This invention relates to acetamide derivatives of the general formula (II) which are activators of glucokinase (GK), and which may be useful for the management, treatment, control, or adjunct treatment of diseases or conditions, where increasing glucokinase activity is beneficial, for example diseases such as IGT, Syndrome X, type 2 diabetes, type 1 diabetes, dyslipidemia, hyperlipidemia, hypertension, and obesity.

  本发明涉及通式（II）的乙酰胺衍生物，它们是葡萄糖激酶（GK）的激活剂，可用于控制、治疗、控制或辅助治疗有益于提高葡萄糖激酶活性的疾病或病症，例如 IGT、X 综合征、2 型糖尿病、1 型糖尿病、血脂异常、高脂血症、高血压和肥胖症等疾病。